New Insights into Therapeutic Targets in Myeloma
New Insights into Therapeutic Targets in Myeloma
复制标题
DOI：
10.1182/asheducation-2011.1.184
复制
发表时间：
2011-12-01
期刊：
影响因子：
--
通讯作者：
Anderson, Kenneth C.
中科院分区：
文献类型：
--
作者：
Anderson, Kenneth C.
由于使用了包括蛋白酶体抑制剂和免疫调节药物在内的联合治疗，多发性骨髓瘤（MM）的患者结局得到了显著改善，这些药物靶向BM微环境中的肿瘤。正在进行的改善治疗模式的努力甚至进一步包括使用癌基因组学来更好地表征分子发病机制并开发MM中的精细患者分层和个性化药物;在其BM环境中使用MM模型来鉴定新靶标并验证针对这些靶标的下一代治疗剂;开发基于免疫的疗法，包括mAb、靶向MM细胞和细胞因子的免疫毒素以及新的疫苗策略;并利用功能性癌基因组学为新型联合治疗的设计提供信息。随着这些领域进展的持续快速发展，MM将成为一种慢性疾病，在大量患者中具有持续完全缓解。
Patient outcome in multiple myeloma (MM) has been remarkably improved due to the use of combination therapies including proteasome inhibitors and immunomodulatory drugs, which target the tumor in its BM microenvironment. Ongoing efforts to improve the treatment paradigm even further include using oncogenomics to better characterize molecular pathogenesis and to develop refined patient stratification and personalized medicine in MM; using models of MM in its BM milieu to identify novel targets and to validate next-generation therapeutics directed at these targets; developing immune-based therapies including mAbs, immunotoxins targeting MM cells and cytokines, and novel vaccine strategies; and using functional oncogenomics to inform the design of novel combination therapies. With continued rapid evolution of progress in these areas, MM will be a chronic illness with sustained complete response in a significant number of patients.